Researchers, including international researchers, who are interested in obtaining the data can contact SCB via information\@scb.se, and Socialstyrelsen via registerservice\@socialstyrelsen.se. One can visit <https://www.scb.se/sv_/Vara-tjanster/Bestalla-mikrodata/(SCB)>, <http://www.socialstyrelsen.se/register/bestalladatastatistik/bestallaindividuppgifterforforskningsandamal> (Socialstyrelsen).

Introduction {#sec007}
============

The leading causes of death and morbidity worldwide are noncommunicable diseases (NCDs), such as chronic respiratory disease, cancer, diabetes, and, in particular, ischemic heart disease and stroke \[[@pmed.1003135.ref001]\]. The impact of these NCDs will probably increase with a growing number of older people in the future \[[@pmed.1003135.ref002]\], imposing great challenges on care systems. However, many NCDs share modifiable risk factors such as smoking, substance abuse, unhealthy diet, and physical inactivity. The World Health Organization (WHO) has concluded that stroke, heart disease, and type 2 diabetes can be prevented by lifestyle change in at least 80% of the individuals affected \[[@pmed.1003135.ref003]\]. In addition, appropriate pharmacological interventions decrease the impact of risk factors such as hypertension and hyperlipidemia.

Thus, there are several incentives to evaluate strategies that may reduce the risk of our most common NCDs. Although preventive measures likely are necessary cornerstones of these strategies, a meta-analysis of randomized controlled trials showed that primary prevention programs involving education and counseling did not reduce the risk of cardiovascular disease (CVD) and death \[[@pmed.1003135.ref004]\]. This lack of effect may relate to the facts that the mean age in the included studies was only 50 years and that the risk factor burden was rather low. The lack of effect in previous studies may also be related to short follow-up times, since preventive measures in midlife may influence the risk of disease many years later. To the best of our knowledge, no large study has previously evaluated the effects of prevention programs in individuals aged 65 years or older, in whom risk factors for CVD are much more common. The aim of the present study was to evaluate the effects of a multiple risk factor program---including collection and evaluation of classic risk factors for CVD such as blood pressure, lipid levels, obesity, and physical inactivity, and feedback to participants---on the risk of ischemic heart disease and stroke in 70-year-old men and women.

Methods {#sec008}
=======

Healthy Ageing Initiative program {#sec009}
---------------------------------

The Healthy Ageing Initiative (HAI) is an ongoing primary prevention study in Umeå, a municipality with 127,000 inhabitants in northern Sweden. The study was initiated in May 2012, and is performed at a single clinic. Three trained research nurses conduct all the testing, with the support of 2 chief physicians (AN and PN). The eligibility criteria are residence in Umeå Municipality and age exactly 70 years. There are no exclusion criteria, and public population registers are used for recruitment. During the years of this study, 54% of 70-year olds in Umeå have participated.

The prevention program used in the HAI project is described in detail in [S1 Appendix](#pmed.1003135.s002){ref-type="supplementary-material"}. In short, all participants arrive fasting at a first visit for measurements of blood glucose and lipids. Other data collected include a comprehensive self-administered health and lifestyle questionnaire; total, gynoid, and visceral fat mass, measured using dual-energy X-ray absorptiometry; waist and hip circumference, measured using a measuring tape; and blood pressure, which is measured in a seated position after at least 10 minutes of rest. Participants are given feedback on their test results (e.g., blood pressure, BMI, and blood glucose) based on cut points from current guidelines. In total this first visit takes about 3 hours. The participants are then sent home with an accelerometer for assessment of physical activity during 1 week. Thereafter, the participants return for a second visit at which all test results form the basis for a motivational interview about diet, exercise, and tobacco and alcohol use. In addition, participants are encouraged to contact their general practitioner for appropriate medication adjustments.

Participants and controls {#sec010}
-------------------------

The aim of the present cohort analysis was to evaluate the HAI prevention program with respect to CVD. The study protocol was registered on ClinicalTrials.gov on 17 October 2017 (NCT03312439), and we received data files for the present project from the National Board of Health and Welfare on 21 December 2018. We hypothesized that the prevention program would reduce the primary outcome of CVD. However, some analyses, such as those on blood pressure and lipid levels, were added in response to reviewers' comments. To evaluate the prevention program, in the primary analysis, we included everyone who participated in HAI during 2012--2017, in total 3,617 individuals, of whom 3,613 had complete data. We created a control group from the general population of Sweden using national registry data. Using the Register of the Total Population \[[@pmed.1003135.ref005]\], we identified controls who resided in Sweden on 31 December 2005 and who were expected to turn 70 years during the analysis period.

In HAI participants, baseline was the date of the HAI health survey. To assign a baseline date to controls, we randomly sampled the time interval between the HAI participants' 70th birthday and the date of their visit. Next, these sampled intervals were added to the controls' 70th birthday. Controls were excluded from the analysis if they were not alive on their assigned baseline date, if they had emigrated, or if this date was not in 2012--2017.

In a secondary analysis, the risk of the outcome was compared between all 70-year-old Umeå residents, irrespective of participation in the HAI project, and 70-year-olds residing in the rest of Sweden who turned 70 years during 2006--2017. This analysis was divided into 2 periods: the 6 years before the start of HAI (2006--2011) and the first 6 years of the study (2012--2017). In both periods, baseline dates for non-HAI participants were randomly assigned as described above.

Confounders {#sec011}
-----------

Data on diagnosed medical and psychiatric conditions were collected from the National Patient Register, a register managed by the National Board of Health and Welfare that covers all inpatient care in Sweden since 1987 and all specialist outpatient care since 2001 \[[@pmed.1003135.ref006]\]. Data on prescription medication use were obtained from the Prescribed Drug Register, which covers all medications sold in Sweden since July 2005. Socioeconomic data (income, education, and civil status) were collected from the registers of Statistics Sweden and the National Board of Health and Welfare \[[@pmed.1003135.ref005]\]. Detailed variable definitions are provided in [S1 Table](#pmed.1003135.s003){ref-type="supplementary-material"}.

Outcomes {#sec012}
--------

The primary outcome was the occurrence of ischemic or hemorrhagic stroke, myocardial infarction, or angina pectoris until 31 December 2017. These events were traced through the National Patient Register using diagnostic codes I20, I21, and I61--I64 (International Classification of Diseases--10th Revision). In addition, for HAI participants, changes in blood pressure and lipid levels and prescription of antihypertensive drugs and lipid-lowering therapy were investigated after the baseline examination. Blood pressure measurements and low-density lipoprotein (LDL)--cholesterol were obtained by using a script to scan all medical records in primary and specialized healthcare, based on the unique personal identity number given to all Swedish residents.

Statistical analysis {#sec013}
--------------------

In the primary analysis, we matched each HAI participant to 4 controls, matching exactly on sex and year of birth, and propensity-score-matching on diagnoses, socioeconomic variables, and prescription medication use (all variables in [Table 1](#pmed.1003135.t001){ref-type="table"}). Propensity scores were estimated using logistic regression. This model included a square term for disposable income, the only continuous covariate. The propensity-score match was created using a nearest-neighbor algorithm without replacement (Psmatch2 package for Stata). Match quality (closeness) was determined using standardized mean differences, where differences of \<0.1 were considered negligible \[[@pmed.1003135.ref007]\]. We compared the risk of the primary outcome in HAI participants and matched controls using Cox regression, a model that was stratified by matched set.

10.1371/journal.pmed.1003135.t001

###### Baseline characteristics of Healthy Ageing Initiative (HAI) participants and the control population before and after matching.

![](pmed.1003135.t001){#pmed.1003135.t001g}

  Variable                                                                  HAI participants   Controls         Standardized mean difference          
  ------------------------------------------------------------------------- ------------------ ---------------- ------------------------------ ------ ------
  ***N***                                                                   3,617              653,747          14,452                                
  **Age, mean (SD), years**                                                 70.5 (0.1)         70.5 (0.1)       70.5 (0.1)                     0.01   0.01
  **Female sex, *n* (%)**                                                   1,824 (50.5)       329,373 (50.7)   9,120 (50.5)                   0.01   0.00
  **Disposable income at age 60 years, mean (SD), 1,000 Swedish kronor**    245 (175)          235 (580)        249 (226)                      0.02   0.02
  Missing data, *n*                                                         0                  462                                                    
  **Education**[^**a**^](#t001fn001){ref-type="table-fn"}**, *n* (%)**                                                                                
  Primary                                                                   613 (16.9)         194,956 (29.8)   2,387 (16.5)                   0.34   0.02
  Secondary                                                                 1,481 (40.9)       278,087 (42.5)   6,104 (42.2)                   0.03   0.03
  Post-secondary                                                            1,519 (42.0)       176,329 (27.0)   5,961 (41.1)                   0.27   0.02
  Missing data, *n*                                                         4                  4,375                                                  
  **Civil status**[^**a**^](#t001fn001){ref-type="table-fn"}**, *n* (%)**                                                                             
  Married                                                                   2,383 (65.9)       395,790 (60.5)   9,529 (65.9)                   0.11   0.00
  Never married                                                             317 (8.8)          71,967 (11.0)    1,233 (8.5)                    0.08   0.01
  Widowed                                                                   284 (7.9)          55,644 (8.5)     1,106 (7.7)                    0.02   0.01
  Divorced                                                                  633 (17.5)         129,313 (19.8)   2,584 (17.9)                   0.06   0.01
  Other, *n*                                                                0                  266                                                    
  Missing data, *n*                                                         0                  767                                                    
  **Diagnoses, *n* (%)**                                                                                                                              
  Stroke                                                                    122 (3.4)          27,215 (4.2)     481 (3.3)                      0.04   0.00
  Myocardial infarction                                                     168 (4.6)          32,515 (5.0)     664 (4.6)                      0.02   0.00
  Heart failure                                                             63 (1.7)           16,115 (2.5)     240 (1.7)                      0.06   0.01
  Angina pectoris                                                           282 (7.8)          47,403 (7.3)     1,125 (7.8)                    0.02   0.00
  Diabetes                                                                  326 (9.0)          88,836 (13.6)    1,368 (9.5)                    0.16   0.02
  Fracture                                                                  570 (15.8)         96,327 (14.7)    2,314 (16.0)                   0.03   0.01
  Rheumatoid arthritis                                                      79 (2.2)           12,629 (1.9)     326 (2.3)                      0.02   0.00
  Chronic obstructive pulmonary disease                                     61 (1.7)           18,912 (2.9)     244 (1.7)                      0.09   0
  Renal failure                                                             27 (0.7)           9,411 (1.4)      125 (0.9)                      0.08   0.02
  Crohn disease                                                             29 (0.8)           5,200 (0.8)      107 (0.7)                      0.00   0.01
  Ulcerative colitis                                                        31 (0.9)           5,803 (0.9)      139 (1.0)                      0.00   0.01
  Parkinson disease                                                         26 (0.7)           4,127 (0.6)      91 (0.6)                       0.01   0.01
  Dementia                                                                  14 (0.4)           6,865 (1.1)      47 (0.3)                       0.11   0.01
  Depression                                                                735 (20.3)         144,008 (22.0)   2,947 (20.4)                   0.04   0.00
  Bipolar disorder                                                          18 (0.5)           4,102 (0.6)      66 (0.5)                       0.04   0.01
  Alcohol intoxication                                                      31 (0.9)           15,335 (2.3)     97 (0.7)                       0.16   0.02
  Opioid intoxication                                                       1 (0.03)           692 (0.1)        2 (0.01)                       0.05   0.01
  Cancer                                                                    676 (18.7)         125,498 (19.2)   2,722 (18.8)                   0.01   0.00
  **Medications**[^**b**^](#t001fn002){ref-type="table-fn"}**, *n* (%)**                                                                              
  Antihypertensive                                                          2,083 (57.6)       357,358 (54.7)   8,490 (58.7)                   0.06   0.02
  Lipid-lowering agent                                                      1,558 (43.1)       256,229 (39.2)   6,260 (43.3)                   0.08   0.00
  Anticoagulant                                                             1,412 (39.0)       257,188 (39.3)   5,641 (39.0)                   0.01   0.00
  Neuroleptic                                                               82 (2.3)           20,793 (3.2)     300 (2.1)                      0.06   0.01
  Hypnotic                                                                  955 (26.4)         176,796 (27.0)   3,861 (26.7)                   0.01   0.01
  Sedative                                                                  378 (10.5)         133,857 (20.5)   1,535 (10.6)                   0.33   0.01
  Immunosuppressant                                                         110 (3.0)          20,357 (3.1)     444 (3.1)                      0.00   0.00

^a^Education and civil status recorded in the calendar year before the baseline date.

^b^Prescriptions filled since July 2005.

In the secondary analysis of 70-year-olds in Umeå and those in the rest of the Sweden, associations were investigated using unconditional Cox regression. To test whether the associations were different in the periods before and after HAI started, an interaction term was created between time period of baseline date (2006--2011 or 2012--2107) and whether individuals were Umeå residents (yes or no). The proportional hazards assumption was evaluated for the models by scaled Schoenfeld residuals. Statistical analyses were performed using Stata version 15.0 (StataCorp, College Station, TX, US) and SPSS version 25.0 (IBM, Armonk, NY, US). *p-*Values \< 0.05 were considered to be significant.

Data linkage and ethics approval {#sec014}
--------------------------------

HAI data and national registry data could be linked by unique personal identity numbers, issued to all residents of Sweden upon birth or immigration. The HAI study and the present analysis were both approved by the Regional Ethical Review Board in Umeå, Sweden (no. 07-031M with extensions). Written informed consent was given by all participants. This paper follows the STROBE reporting guideline ([S1 STROBE](#pmed.1003135.s001){ref-type="supplementary-material"} Checklist).

Results {#sec015}
=======

Study cohort {#sec016}
------------

For the primary analysis, data were available for 3,617 HAI participants (of whom 3,613 had complete data) and 734,359 potential controls born in 1942--1947. Potential controls were excluded (*n =* 80,612) if they emigrated before the assigned baseline date, if the baseline date was out of range, i.e., not in 2012--2017, or if the baseline date was after their date of death. Thus, there were 3,613 eligible HAI participants and 653,747 eligible controls. Propensity-score matching resulted in a final cohort of 3,613 HAI participants and 14,452 controls with similar baseline characteristics ([Table 1](#pmed.1003135.t001){ref-type="table"}). Additional baseline characteristics for participants, collected in the HAI health study are provided in [Table 2](#pmed.1003135.t002){ref-type="table"}. Baseline characteristics for all Umeå residents are presented in [Table 3](#pmed.1003135.t003){ref-type="table"}. Individuals who participated in HAI were generally healthier, with lower prevalence of CVD and diabetes, than Umeå residents who did not participate.

10.1371/journal.pmed.1003135.t002

###### Additional baseline characteristics collected from participants in the Healthy Ageing Initiative study.

![](pmed.1003135.t002){#pmed.1003135.t002g}

  Variable                                                        Total cohort (*n =* 3,617)   Women (*n =* 1,817)   Men (*n =* 1,800)
  --------------------------------------------------------------- ---------------------------- --------------------- -------------------
  **Body composition**                                                                                               
  Height (cm)                                                     170 ± 9                      163 ± 6               176 ± 6
  Weight (kg)                                                     77.0 ± 15.0                  70.3 ± 13.0           83.7 ± 12.9
  BMI (kg/m^2^)                                                   26.6 ± 4.3                   26.4 ± 4.7            26.8 ± 3.8
  Waist circumference (cm)                                        94 ± 13                      89 ± 12               99 ± 11
  Hip circumference (cm)                                          103 ± 8                      103 ± 9               102 ± 7
  Total fat mass (grams)[\*](#t002fn002){ref-type="table-fn"}     27,645 ± 9,089               28,887 ± 9,364        26,389 ± 8,624
  Gynoid fat mass (grams)[\*](#t002fn002){ref-type="table-fn"}    4,020 ± 1,418                4,604 ± 1,434         3,429 ± 1,128
  Android fat mass (grams)[\*](#t002fn002){ref-type="table-fn"}   2,748 ± 1,190                2,586 ± 1,158         2,912 ± 1,199
  **Blood pressure**                                                                                                 
  Systolic (mm Hg)                                                139 ± 17                     140 ± 17              138 ± 16
  Diastolic (mm Hg)                                               81 ± 9                       81 ± 9                82 ± 9
  **Blood glucose (mmol/l)**                                      5.7 ± 1.2                    5.6 ± 1.3             5.8 ± 1.2
  **Blood lipids (mmol/l)**                                                                                          
  Total cholesterol                                               5.4 ± 1.2                    5.8 ± 1.1             5.1 ± 1.2
  Low-density lipoprotein cholesterol                             3.3 ± 1.1                    3.5 ± 1.1             3.0 ± 1.0
  High-density lipoprotein cholesterol                            1.6 ± 0.5                    1.7 ± 0.5             1.4 ± 0.4
  Triglycerides                                                   1.3 ± 0.7                    1.3 ± 0.7             1.4 ± 0.7
  **Accelerometer-measured physical activity (steps/day)**        7,331 ± 3,093                7,298 ± 3,132         7,364 ± 3,052
  **Current smoker (*n*, %)**                                     214, 5.9%                    119, 6.5%             95, 5.3%

Except where otherwise noted, data are mean ± standard deviation.

\*Measured by dual-energy X-ray absorptiometry.

10.1371/journal.pmed.1003135.t003

###### Baseline characteristics of 70-year-old Umeå residents and 70-year-old residents from the rest of Sweden.

![](pmed.1003135.t003){#pmed.1003135.t003g}

  Variable                                                                  Baseline date 2006--2011   Baseline date 2012--2017                                          
  ------------------------------------------------------------------------- -------------------------- -------------------------- ------ -------------- ---------------- ------
  ***N***                                                                   4,495                      446,860                           6,665          650,699          
  **Age, mean (SD), years**                                                 70.5 (0.1)                 70.5 (0.1)                 0.02   70.5 (0.1)     70.5 (0.1)       0.00
  **Female sex, *n* (%)**                                                   2,369 (53.9)               230,478 (51.6)             0.05   3,371 (50.6)   329,993 (50.7)   0.00
  **Disposable income at age 60 years, mean (SD), 1,000 Swedish kronor**    185 (230)                  179 (348)                  0.01   237 (366)      235 (580)        0.00
  Missing data, *n*                                                         0                          148                               0              452              
  **Education**[^**a**^](#t003fn003){ref-type="table-fn"}**, *n* (%)**                                                                                                   
  Primary                                                                   1,326 (30.3)               178,877 (40.0)             0.23   1,400 (21.0)   194,169 (29.8)   0.22
  Secondary                                                                 1,875 (42.8)               168,665 (38.0)             0.10   2,823 (42.4)   276,745 (42.5)   0.00
  Post-secondary                                                            1,179 (26.9)               92,400 (20.7)              0.15   2,429 (36.4)   175,419 (27.0)   0.20
  Missing data, *n*                                                         15                         5,918                             13             4,366            
  **Civil status**[^**a**^](#t003fn003){ref-type="table-fn"}**, *n* (%)**                                                                                                
  Married                                                                   2,840 (64.6)               277,076 (62.0)             0.06   4,047 (60.7)   394,126 (60.6)   0.00
  Never married                                                             323 (7.3)                  37,211 (8.3)               0.04   794 (11.9)     71,490 (11.0)    0.03
  Widowed                                                                   492 (11.2)                 49,763 (11.1)              0.00   552 (8.3)      55,376 (8.5)     0.01
  Divorced                                                                  740 (16.8)                 82,370 (18.4)              0.05   1,272 (19.1)   128,674 (19.8)   0.02
  Other, *n*                                                                0                          124                               0              266              
  Missing data, *n*                                                         0                          316                               0              767              
  **Diagnoses, *n* (%)**                                                                                                                                                 
  Stroke                                                                    204 (4.6)                  17,614 (3.9)               0.04   319 (4.8)      27,018 (4.2)     0.04
  Myocardial infarction                                                     163 (3.7)                  20,375 (4.6)               0.05   352 (5.3)      32,331 (5.0)     0.02
  Heart failure                                                             116 (2.6)                  10,739 (2.4)               0.02   174 (2.6)      16,004 (2.5)     0.01
  Angina pectoris                                                           383 (8.7)                  35,919 (8.0)               0.03   540 (8.1)      47,145 (7.2)     0.04
  Diabetes                                                                  451 (10.3)                 52,056 (11.6)              0.05   820 (12.3)     88,142 (13.5)    0.05
  Fracture                                                                  506 (11.5)                 45,364 (10.2)              0.05   1,132 (17.0)   95,765 (14.7)    0.08
  Rheumatoid arthritis                                                      95 (2.2)                   7,638 (1.7)                0.04   142 (2.1)      12,556 (1.9)     0.02
  Chronic obstructive pulmonary disease                                     131 (3.0)                  10,808 (2.4)               0.04   185 (2.8)      18,788 (2.9)     0.01
  Renal failure                                                             39 (0.9)                   4,007 (0.9)                0.00   91 (1.4)       9,347 (1.4)      0.01
  Crohn disease                                                             19 (0.4)                   2,327 (0.5)                0.01   48 (0.7)       5,181 (0.8)      0.01
  Ulcerative colitis                                                        28 (0.6)                   2,645 (0.6)                0.01   48 (0.7)       5,786 (0.9)      0.03
  Parkinson disease                                                         36 (0.8)                   2,613 (0.6)                0.03   56 (0.8)       4,097 (0.6)      0.03
  Dementia                                                                  80 (1.8)                   4,726 (1.1)                0.06   85 (1.3)       6,794 (1.0)      0.03
  Depression                                                                695 (15.8)                 66,112 (14.8)              0.03   1,525 (22.9)   143,218 (22.0)   0.03
  Bipolar disorder                                                          11 (0.3)                   1,968 (0.4)                0.04   48 (0.7)       4,072 (0.6)      0.02
  Alcohol intoxication                                                      63 (1.4)                   6,873 (1.5)                0.01   129 (1.9)      15,237 (2.3)     0.04
  Opioid intoxication                                                       1 (0.02)                   203 (0.05)                 0.02   3 (0.05)       650 (0.1)        0.03
  Cancer                                                                    652 (14.8)                 66,400 (14.9)              0.00   1,257 (18.9)   124,917 (19.2)   0.01
  **Medications**[^**b**^](#t003fn004){ref-type="table-fn"}**, *n* (%)**                                                                                                 
  Antihypertensive                                                          2,455 (55.9)               210,518 (47.1)             0.19   4,072 (61.1)   355,369 (54.6)   0.14
  Lipid-lowering agent                                                      1,589 (36.2)               144,738 (32.4)             0.09   2,990 (44.9)   254,797 (39.2)   0.11
  Anticoagulant                                                             1,607 (36.6)               153,512 (34.4)             0.05   2,803 (42.1)   255,797 (39.3)   0.06
  Neuroleptic                                                               162 (3.7)                  12,565 (2.8)               0.05   271 (4.1)      20,604 (3.2)     0.05
  Hypnotic                                                                  1,004 (22.8)               94,302 (21.1)              0.05   1,861 (27.9)   175,890 (27.0)   0.02
  Sedative                                                                  360 (8.2)                  63,296 (14.2)              0.23   848 (12.7)     133,387 (20.5)   0.23
  Immunosuppressant                                                         122 (2.8)                  9,309 (2.1)                0.05   247 (3.7)      20,220 (3.1)     0.03

Data are presented for those with a baseline date before (years 2006--2011) and after (years 2012--2017) the Healthy Ageing Initiative program started.

\*Standardized mean difference.

^a^Education and civil status recorded in the calendar year before the baseline date.

^b^Prescriptions filled since July 2005.

Outcome of stroke, myocardial infarction, or angina pectoris {#sec017}
------------------------------------------------------------

The matched cohort (*n =* 18,065) was followed for a mean of 2.5 years (range 0--6 years) ([Fig 1](#pmed.1003135.g001){ref-type="fig"}). During follow-up, the primary outcome of stroke, myocardial infarction, or angina pectoris occurred in 128 (3.5%) HAI participants and 636 (4.4%) controls (hazard ratio \[HR\] 0.80, 95% CI 0.66--0.97, *p =* 0.026). The HR was similar in the male (HR 0.78, 95% CI 0.62--0.99, *p =* 0.046) and female (HR 0.79, 95% CI 0.57--1.11, *p =* 0.31) subcohorts.

![Risk of stroke, myocardial infarction, or angina pectoris in participants of the Healthy Ageing Initiative (HAI, *n =* 3,613) and matched controls (*n =* 14,452).\
The hazard ratio (HR) is presented for the time to first outcome, and below the figure the number at risk at each time point is presented, together with the number of outcome events within parentheses.](pmed.1003135.g001){#pmed.1003135.g001}

In a secondary analysis, we compared the risk of the primary outcome in all 70-year-old Umeå residents to that in 70-year-old individuals in the rest of Sweden ([Table 3](#pmed.1003135.t003){ref-type="table"}). At baseline, the groups were similar in most respects, the exceptions being education and use of antihypertensives, lipid-lowering agents, and sedatives. In the 6-year period before HAI started (years 2006--2011), the primary outcome occurred in 284 (6.5%) Umeå residents, compared to 27,274 (6.1%) individuals from the rest of Sweden (HR 1.06, 95% CI 0.94--1.19, *p =* 0.33; [Fig 2](#pmed.1003135.g002){ref-type="fig"}). This association changed marginally after adjusting for all confounders (HR 1.04, 95% CI 0.93--1.17, *p =* 0.51). In contrast, during the first 6 years of the HAI prevention program (years 2012--2017), in which 54% of Umeå residents participated, the outcome occurred in 291 (4.4%) Umeå residents and 31,851 (4.9%) residents of the rest of Sweden (HR 0.87, 95% CI 0.77--0.97, *p =* 0.03 for interaction; [Fig 3](#pmed.1003135.g003){ref-type="fig"}), after adjustment for all confounders.

![Risk of stroke, myocardial infarction, or angina pectoris in 70-year-old Umeå residents and in 70-year-olds from the rest of Sweden with baseline date in 2006--2011.\
The hazard ratio (HR) is presented for time to first outcome, and below the figure the number at risk at each time point is presented, together with the number of outcome events within parentheses.](pmed.1003135.g002){#pmed.1003135.g002}

![Risk of stroke, myocardial infarction, or angina pectoris in 70-year-old Umeå residents and in 70-year-olds from the rest of Sweden with baseline date in 2012--2017.\
The hazard ratio (HR) is presented for time to first outcome, and below the figure the number at risk at each time point is presented, together with the number of outcome events within parentheses.](pmed.1003135.g003){#pmed.1003135.g003}

Blood pressure and LDL-cholesterol in HAI participants {#sec018}
------------------------------------------------------

In the 3,617 HAI participants, 53.6% had hypertension stage 2 at baseline (blood pressure ≥ 140/90 mm Hg), irrespective of treatment, and 1,541 (42.6%) of the participants were not prescribed any antihypertensive drug before participation in the HAI project. In this group, antihypertensive drug use after participation in HAI was related to blood pressure at baseline in HAI ([Fig 4](#pmed.1003135.g004){ref-type="fig"}). Thus, in individuals with blood pressure of \<130/80 mm Hg at baseline, 4.5% were after HAI prescribed at least 1 dose of antihypertensives, compared to 50.5% of individuals with a systolic blood pressure of at least 160 mm Hg or a diastolic blood pressure of at least 100 mm Hg at baseline (*p \<* 0.001 for comparison). After HAI, we could track a total of 7,744 blood pressure measurements performed in 3,126 HAI participants, at general practitioners or in specialist healthcare. For individuals in HAI with a systolic blood pressure of less than 130 and a diastolic blood pressure of less than 80 mm Hg (*n =* 517) at baseline, the follow-up measurements showed that mean systolic blood pressure increased by 9.0 mm Hg (95% CI 7.4--10.6, *p \<* 0.001), and mean diastolic blood pressure increased nonsignificantly by 0.4 mm Hg (95% CI −0.2 to 0.9, *p =* 0.16) during follow-up (Figs [5](#pmed.1003135.g005){ref-type="fig"} and [6](#pmed.1003135.g006){ref-type="fig"}). In contrast, for participants with a systolic blood pressure of at least 160 mm Hg or a diastolic blood pressure of at least 100 mm Hg (*n =* 434) at baseline, mean systolic blood pressure decreased by 21.8 mm Hg (95% CI 19.8--23.8, *p \<* 0.001), and mean diastolic blood pressure decreased by 9.6 mm Hg (95% CI 8.6--10.6, *p \<* 0.001) after baseline (Figs [5](#pmed.1003135.g005){ref-type="fig"} and [6](#pmed.1003135.g006){ref-type="fig"}).

![Initiation of blood pressure treatment in treatment-naïve Healthy Ageing Initiative (HAI) participants based on blood pressure category at baseline (*n =* 1,541).\
Hypertension stage 1: systolic blood pressure of 130--139 mm Hg or diastolic blood pressure of 80--89 mm Hg. Hypertension stage 2: systolic blood pressure of ≥140 mm Hg or diastolic blood pressure of ≥90 mm Hg.](pmed.1003135.g004){#pmed.1003135.g004}

![Changes in systolic blood pressure after the baseline examination in Healthy Ageing Initiative (HAI) participants, based on blood pressure category at baseline.\
The figure is based on a total of 7,744 follow-up measurements in 3,126 HAI participants. Means and standard deviations are presented. Hypertension stage 1: systolic blood pressure of 130--139 mm Hg or diastolic blood pressure of 80--89 mm Hg. Hypertension stage 2: systolic blood pressure of ≥140 mm Hg or diastolic blood pressure of ≥90 mm Hg. BT, blood pressure.](pmed.1003135.g005){#pmed.1003135.g005}

![Changes in diastolic blood pressure after the baseline examination in Healthy Ageing Initiative (HAI) participants, based on blood pressure category at baseline.\
The figure is based on a total of 7,744 follow-up measurements in 3,126 HAI participants. Means and standard deviations are presented. Hypertension stage 1: systolic blood pressure of 130--139 mm Hg or diastolic blood pressure of 80--89 mm Hg. Hypertension stage 2: systolic blood pressure of ≥140 mm Hg or diastolic blood pressure of ≥90 mm Hg. BT, blood pressure.](pmed.1003135.g006){#pmed.1003135.g006}

In the HAI participants, 2,055 individuals (55.9%) were not treated with lipid-lowering therapy at baseline. In these individuals, lipid-lowering therapy after baseline was initiated based on LDL-cholesterol level at baseline ([Fig 7](#pmed.1003135.g007){ref-type="fig"}). After baseline, 6,631 follow-up measurements of LDL-cholesterol were obtained in 2,347 individuals from the HAI cohort. As was the case for blood pressure, LDL-cholesterol levels were reduced depending on the LDL-levels at baseline ([Fig 8](#pmed.1003135.g008){ref-type="fig"}). For those with LDL-cholesterol levels above 4.11 mmol/l at baseline, a mean reduction of 1.3 mmol/l was seen more than 2 years after the initial measurement. In contrast, LDL-cholesterol did not change in those with LDL-cholesterol \< 3.36 mmol/l at baseline.

![Initiation of lipid-lowering therapy (statin) in treatment-naïve Healthy Ageing Initiative (HAI) participants based on low-density lipoprotein (LDL)--cholesterol levels obtained at baseline (*n =* 2,055).](pmed.1003135.g007){#pmed.1003135.g007}

![Changes in low-density lipoprotein (LDL)--cholesterol levels after the baseline examination in Healthy Ageing Initiative (HAI) participants, based on LDL-cholesterol at baseline.\
The figure is based on a total of 6,631 measurements in 2,347 HAI participants. Participants were categorized in 3 groups based on LDL-cholesterol level at baseline: optimal (\<3.36 mmol/l, blue line), intermediate (3.36--4.11 mmol/l, orange line), and high (\>4.11 mmol/l, gray line). Means and standard deviations are presented.](pmed.1003135.g008){#pmed.1003135.g008}

Discussion {#sec019}
==========

In community-dwelling 70-year-olds, a multidimensional prevention program was associated with a 20% lower risk of CVD during follow-up. Consistent with the main results, the risk of CVD was lower in 70-year-olds in the prevention program municipality than in the rest of Sweden after, but not before, the HAI project was initiated. An analysis of intermediate outcomes in HAI participants showed that detected hypertension and high blood lipids at baseline were associated with initiation of therapy, and greater reductions in these risk factors during follow-up.

To our knowledge, no large randomized or observational study has evaluated the effects of multidimensional prevention programs on CVD in people aged 65 years or older. In people aged 50 years on average, a meta-analysis of randomized intervention studies found no effect of such programs on all-cause mortality or coronary heart disease mortality \[[@pmed.1003135.ref004]\]. The associations found in the present project could be related to the participants' older age and greater number of risk factors at baseline. In support of this hypothesis, the mentioned meta-analysis did find significant effects on all-cause mortality and CVD in participants with diabetes or hypertension \[[@pmed.1003135.ref004]\]. It has also been demonstrated previously that the importance of risk factors for CVD increase with increasing age \[[@pmed.1003135.ref008]\].

In addition to the risk factor burden in the study population, the success of a primary prevention program may be determined by the risk factor the program is targeting, and if the program is modifying a single risk factor or the total risk factor burden. Recently, the Look AHEAD Research Group found that an intervention program targeting weight loss had no effect on death or CVD in a large randomized study of overweight and obese individuals with type 2 diabetes \[[@pmed.1003135.ref009]\]. According to the authors, one reason for the lack of effect could be good medical management of risk factors for CVD in primary care, i.e., risk factors other than obesity. This is an important point, since the most important risk factor for CVD and mortality is probably hypertension \[[@pmed.1003135.ref010]--[@pmed.1003135.ref012]\]. In the Look AHEAD study population, systolic blood pressure was on average 130 mm Hg at baseline \[[@pmed.1003135.ref009]\], suggesting a rather good adherence to current knowledge and guidelines \[[@pmed.1003135.ref013]\], which likely influenced the chance to show an effect of the intervention. In our population, about 50% had stage 2 hypertension at baseline \[[@pmed.1003135.ref014]\], irrespective of pharmacological treatment, suggesting excellent opportunities for improved blood pressure control.

As such, we were interested in also investigating changes in blood pressure and the use of blood pressure medications after the HAI prevention program. In participants with baseline blood pressure below 130/80 mm Hg, 4.5% were dispensed a hypertension drug for the first time during follow-up. In contrast, about 50% of participants were prescribed an antihypertensive for the first time after baseline if they had a systolic blood pressure of at least 160 mm Hg or a diastolic blood pressure of at least 100 mm Hg. These prescription patterns, favoring those with higher blood pressure, were accompanied by a blood pressure reduction during follow-up, especially for those with severe hypertension at baseline. Thus, in participants with a blood pressure of at least 160/100 mm Hg, there was a fast reduction of blood pressure after baseline, and based on all measurements, a mean reduction in systolic blood pressure of 22 mm Hg during follow-up. We also evaluated whether the prevention program was associated with improved control of hypercholesterolemia. Similar to the findings for blood pressure, treatment with lipid-lowering agents was initiated after baseline based on the lipid levels at the initial investigation within HAI. Furthermore, LDL-cholesterol during follow-up decreased based on these prescription patterns. In individuals with LDL-cholesterol levels above 4.11 mmol/l at baseline, a mean reduction of 1.3 mmol/l was seen more than 2 years after the initial measurement. In contrast, for those with optimal lipid levels at baseline, no changes were seen during follow-up. Based on the results of randomized controlled studies, it is quite clear that such reductions in blood pressure and blood lipids are associated with a substantial risk reduction for CVD \[[@pmed.1003135.ref015]\].

Studies have indicated that risk factors for CVD, such as blood pressure and diabetes, are better at predicting disease in older than in younger age groups \[[@pmed.1003135.ref016]--[@pmed.1003135.ref018]\], probably in part because older people have more risk factors. Since interventions are usually more effective in groups with many risk factors \[[@pmed.1003135.ref019]\], these are good reasons to include older people in primary prevention programs. Of our participants, 6% were smokers, the majority were overweight, about 50% had stage 2 hypertension at baseline irrespective of treatment, and 25% had diabetes or fasting glucose impairment. Yet, this burden of risk factors is modest from a global perspective. According to the American Heart Association, more than 60% of Americans aged 65--74 years have hypertension \[[@pmed.1003135.ref020]\]. In Europe, a recent study of 17 countries showed that 11.5% of Europeans are smokers \[[@pmed.1003135.ref021]\]. Thus, any effects of our prevention program were likely not related to an unusually high risk factor burden in the study population. The above-mentioned studies also indicate that it would be of high interest to investigate the effects of preventive measures on the risk of CVD in older people from other countries with an even higher risk factor burden.

Although the risk factor burden in our population may be regarded as modest in an international perspective, it would have been unethical to randomize participants to the prevention program. The disadvantage of not randomizing is that the associations found may be explained by confounding, although participants and controls were matched closely on many potential confounders at baseline. To investigate further the possibility of confounding, we performed a sensitivity analysis that showed that the risk of stroke or ischemic heart disease was similar in Umeå Municipality and the rest of Sweden prior to the start of the prevention program. Thus, 70-year-old Umeå residents overall were probably not healthier than controls due to self-selection, as the presence of CVD was similar in Umeå and the rest of Sweden before the HAI project started. In contrast, the risk of ischemic heart disease and stroke was 13% lower in 70-year-olds living in Umeå after the start of the prevention program---in which 54% of 70-year-olds living in Umeå Municipality participated. The consistent results of these analyses suggest that confounding does not explain our findings. Different components of the prevention program may have contributed to the lower risk of CVD found in HAI participants: There may have been improved medication using drugs known to reduce the risk of CVD, and the motivational interview, including advice with respect to food intake and increased physical activity, may have contributed to the lower risk of CVD. Interestingly, a recent meta-epidemiological study suggested that exercise and drug interventions have similar mortality benefits and effects in the secondary prevention of ischemic heart disease \[[@pmed.1003135.ref022]\]. Future studies are needed to investigate whether these findings are generalizable to other populations of community-dwelling older people.

There are several limitations of the present study that should be acknowledged. In particular, this is an observational study, and the associations found are not proof of causal effects. However, as explained above, given the risk factor burden, a randomized trial in this population could not have been performed due to ethical reasons. We investigated changes in the intermediate endpoints blood pressure and lipid levels to evaluate whether the lower risk of CVD in the HAI participants could be explained by changes in these risk factors. As discussed above, reductions in both blood pressure and lipid levels were seen, especially in those with higher values at baseline. Although this may support the main association found with respect to reduced risk of CVD, these changes were also most likely influenced by regression towards the mean. Therefore, we can only speculate as to whether any effects on CVD are related to changes in blood pressure and lipid levels from improved medication and/or from behavior changes from the motivational interview. The strengths of the study include the large sample of 70-year-olds included in this study and endpoints of high relevance, captured with high precision in national registers with a low loss to follow-up. Given that the cohort investigated is population based, the results are likely generalizable to other 70-year-old men and women.

In summary, a multidimensional primary prevention program was associated with a reduced risk of ischemic heart disease and stroke in community-dwelling 70-year-olds. The prevention program was also associated with improved treatment of hypertension and hypercholesterolemia, particularly in participants at higher risk. Given that the risk factor burden was modest compared to in other countries, it would be interesting and important to see evaluations of similar programs elsewhere. Since the world's population is ageing, primary prevention will probably play a key role in healthcare in the future.

Supporting information {#sec020}
======================
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Click here for additional data file.
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Click here for additional data file.
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11 Mar 2020

Dear Dr. Nordström,

Thank you very much for submitting your manuscript \'A multiple risk factor intervention is associated with decreased risk of cardiovascular disease in 70-year-olds: A Cohort Study\' (PMEDICINE-D-19-03481) for consideration at PLOS Medicine. I sincerely apologise for the delay to your submission as we had some difficulty securing reviewers. I hope you will find their comments useful.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also sent to independent peer reviewers, whose comments you can read at the bottom of this email. Any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

We would like to consider a revised version that addresses the reviewers\' and editors\' comments. Please note that we cannot make any decision about publication until we have seen the revised manuscript and your response, and we may seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration here, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to any comments from reviewers or editors and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>.

While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pace.apexcovantage.com/> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by Mar 31 2020 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \'Submissions Needing Revision\' folder.

We look forward to receiving your revised manuscript.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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Requests from the editors:

Title- please consider amending your title to avoid the use of "intervention" as this suggests the study is a clinical trial or related to one.

Abstract- please consider providing additional background information to place the study into context

Abstract methods and findings-please provide brief participant demographics

Abstract methods and findings- the last sentence should highlight the limitation of your study design

On page 3- please include the heading "Author Summary"

Author summary- please revise to clarify that the authors did not undertake the health survey themselves as it currently reads as an intervention from a clinical trial. Please also provide exact p-values

References- please place square brackets after the full stop for example: \[3\].

Introduction- Line 5 paragraph 1, we suggest "fortunately" is removed here

Introduction-Line 5 paragraph 2 lack of "effect" instead of "effects"

Page 4 last sentence- please rephrase this to sound less like a clinical trial and more as a cohort study

Methods- if there is a reason to choose participants exactly at the age of 70, could you please mention this

Methods- please report the study in line with STROBE guidelines and provide the completed checklist as supplementary information. In the methods, please mention the study has been reported according to the STROBE guideline and the checklist can be found as SI file xx. The STROBE guideline can be found here: <http://www.equator-network.org/reporting-guidelines/strobe/> When completing the checklist, please use section and paragraph numbers, rather than page numbers.

For all observational studies, in the manuscript text, please indicate: (1) the specific hypotheses you intended to test, (2) the analytical methods by which you planned to test them, (3) the analyses you actually performed, and (4) when reported analyses differ from those that were planned, transparent explanations for differences that affect the reliability of the study\'s results. If a reported analysis was performed based on an interesting but unanticipated pattern in the data, please be clear that the analysis was data-driven.

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Please provide the questionnaires used as part of the intervention and also describe the motivational interview in greater detail. Please describe who undertook the interviews, which language were this conducted in, were there any prepared questions or were these open ended.

Please provide brief details of HLA, including follow-up visits, medication prescribing etc

Please provide details of informed consent in the methods section where you note the ethics approval received

Please provide p-values along with all 95% confidence intervals and vice versa. Please provide exact p-values unless p\<0.001

Please note we do not permit instances of data not shown as per PLOS data policy (on page 10). Please provide these data or remove this reference.

Page 12 second paragraph- please revise "hypertension drugs"

We understand that the primary data cannot be shared due to legal and ethical restrictions. Authors do not need to submit their entire data set, or the raw data collected during an investigation. Please submit the following data:

The values behind the means, standard deviations and other measures reported;

The values used to build graphs;

Comments from the reviewers:

Reviewer \#1: I confine my remarks to statistical aspects of this paper. These were very well done and I have only some minor comments.

NOTE: Line numbers would have made the review easier

p\. 2 First para. Not staitistical but \... prevention of what?

p\. 4 Another reason that other studies may have shown small effects is limited follow up time. i.e. Changes that a 40 year old makes may affect his or her chances of having a heart attack at 60 or 70, but few studies are on that time frame.

p\. 7 Why was a quadratic for income added? Why not a spline?

p\. 9 Bottom - Which number had to be higher? Systolic, diastolic, both?

Table 2 - you need to say what the numbers are (mean and sd? Or what)

Figure 4 (several) if you add jitter, it will be easier to see what is going on.

Reviewer \#2: This manuscript evaluated the prevention effects of a multidimensional CVD prevention program, the Healthy Ageing Initiative (HAI), among a community-dwelling senior population who were 70 years old at baseline. The intervention effectiveness was evaluated using two approaches, a propensity score matched case control design and an intention to treat analysis comparing all Umea residents with 70-year-olds who live in other parts of Sweden. Both designs showed the intervention significantly reduced the CVD risk among those who participated in the intervention.

In general, this study is well designed and clearly written. However, I have a few concerns that need to be addressed.

Major Concerns:

1\. My major concern for this study is that the analysis to examine the intervention effects on the control of blood pressure and lipid levels was not done properly. Specifically:

1\) First, the intervention effects on these outcomes were only assessed among the HAI participants, but not in the controls. However, without comparing the outcomes between cases and controls, it is hard to conclude that the improvements in blood pressure and lipid levels were caused by the intervention.

2\) The authors showed that systolic blood pressure among HAI participants increased over time in those with normal baseline blood pressure but decreased among those with very high blood pressure at baseline. This observation is likely caused by \"regression toward the mean\", at least partially.

3\) The changes in blood pressure and lipid levels were assessed using the mean and standard deviations among those who had data at each time point. As the sample sizes changed a lot at different time points, the raw means at different time points are not directly comparable. To make the conclusions more convincible, it is important to compare the means at different time points using a longitudinal model, such as linear mixed model.

2\. Another major concern I have is that the authors did not include a limitation subsection in the Discussion section. Although several paragraphs in the Discussion section described some limitations of the current study, it will be helpful to put all the potential limitations together for the readers to realize these issues fairly easily.

Minor Concerns:

1\. Page 9, last paragraph: It is unclear what percentages they report in the last paragraph on this page. For example, what\'s the denominator for the percentages shown in the second line of this paragraph?

2\. Page 13, first line: What are the other risk factors mentioned in the first sentence?

3\. Page 14, 1st paragraph, line 5-6: The meaning of the sentence started with \"Different components\" is unclear and needs to be clarified.

4\. Page 14, 1st paragraph, line 6: It\'s better to change \"possibility\" to \"opportunity\" in this sentence.

5\. Figure 2a and Figure 2b can be merged into one figure.

Reviewer \#3: In this manuscript entitled \"A multiple risk factor intervention is associated with decreased risk of cardiovascular disease in 70-year-olds: A Cohort Study\", the authors present findings from a cohort study in which the effect of a program aimed at cardiovascular primary prevention on a composite outcome of stroke, myocardial infarction and angina. The study included adults aged 70 living in Sweden. The intervention included a review of the participant\'s cardiovascular risks along with motivational interviewing techniques on cardiovascular risk reduction. The authors used propensity score matching and during a mean follow up of 2.5 years, identified a reduced risk of the primary outcome in participants who received the intervention.

This study and analysis was well designed and the authors recruited a large number of participants in a single site. I have a few points for the authors to consider.

Major

Abstract

1\. Please state the aim of the study more clearly. Consider including the primary outcome and more detail on the nature of the primary prevention program.

Introduction

1\. Consider stating the hypothesis and aim of this study explicitly in the introduction

2\. Consider explaining the \"multiple risk factor intervention\" in more detail in this section

Methods

1\. Was a sample size estimation completed for this study?

2\. Did the authors consider conducting a randomized controlled trial and what were the reasons for choosing a cohort study design?

3\. 54% of residents enrolled in the study. Is it known why 46% of residents did not participate and are demographic details available for this cohort?

Results

1\. Is it possible the observed result was due solely to prescription of lipid lowering therapy and antihypertensives and not the intervention?

2\. There were higher rates of antihypertensive and lipid lowering therapies in the Umea general population. Was there a difference in prescribing rates between Umea residents who were and were not participants in the study?

Discussion

1\. This study found that participants were more likely to be prescribed blood pressure and lipid lowering therapy by their primary care doctor - can the authors elaborate further on how the motivational interview techniques conferred benefit in addition to this?

Minor

Methods

1\. Consider stating the study type early in the Methods section eg. cohort study

2\. Stroke was included in the composite primary outcome. Was this ischemic, hemorrhagic stroke or both?

3\. \"Feedback is given continuously\" - can you describe in more detail what form this feedback took?

References

1\. Citation number 8 is invalid

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003135.r002
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15 Apr 2020

Dear Dr. Nordström,

Thank you very much for re-submitting your manuscript \"A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A Cohort Study\" (PMEDICINE-D-19-03481R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by 3 reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Apr 22 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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Comments from the Academic Editor:

I would like to see the authors make a more explicit statement in the abstract and in the limitations sections that the BP and LDL improvements are very likely influenced by regression to the mean as pointed out by one of the reviewers. I think they overstate the potential benefits of these reductions when we have no way of knowing what happened in the control group.

On the prescription data I may be missing something but why is this information not available for the control group from the Prescribed Drug Register. If there was an overall increase in prescription rate and/or drug dispensing rates over the follow-up period in the HAI group, that would be stronger evidence to support the assertion that the program did drive better BP and LDL control in the absence of these data in the control group. I appreciate that this may not be able to be disaggregated by baseline lipid and BP levels as done in Fig 3 and 5 for the control group but an overall comparison would add considerable information. I also think that looking at dispensing of scripts as it is a reasonably robust measure of adherence.

xxx

Requests from Editors:

Title- Could we add Sweden to the title?

Abstract

Please include limitations of your study design as the last sentence of the methods and findings section

Abstract Conclusions:

\* Please address the study implications without overreaching what can be concluded from the data; the phrase \"In this study, we observed \...\" may be useful.

\* Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

\* Please avoid vague statements such as \"these results have major implications for policy/clinical care\". Mention only specific implications substantiated by the results.

\* Please avoid assertions of primacy (\"We report for the first time\....\")

Lines 13-16 -- please replace "intervention" with a more appropriate word

Please briefly include limitations in the author summary section "what do these findings mean"

Methods

Line 5, 7 please rephrase "intervention program".

STROBE checklist- please remove page numbers as these are likely to change during publication

Discussion

Several instances of "intervention". Please rephrase

Comments from Reviewers:

Reviewer \#1: The authors have addressed my concerns and I now recommend publication.

My only issue is their response to my last question \-- I don\'t know how this works at PLOS and so, I leave it to the editors.

Peter Flom

Reviewer \#2: This revision has substantially improved the manuscript and addressed all of my previous concerns.

Reviewer \#3: In this revised manuscript entitled \"A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A Cohort Study\", the authors addressed the points raised by the reviewers.

This study and analysis was well designed. However, the observed outcomes have several limitations and I do not feel the findings of this study are novel or impact on direct patient care enough to recommend publication.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003135.r003
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11 May 2020

Dear Dr. Nordström,

On behalf of my colleagues and the academic editor, Dr. David Peiris, I am delighted to inform you that your manuscript entitled \"A multiple risk factor program is associated with decreased risk of cardiovascular disease in 70-year-olds: A cohort study from Sweden\" (PMEDICINE-D-19-03481R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor
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